Concomitant occurrence of pulmonary invasive aspergillosis and pneumocystis pneumonia during FOLFIRINOX chemotherapy for pancreatic carcinoma

Pancreas

Volumn 42, Issue 1, 2013, Pages 178-180

  Péron, Julien ^a   Derbel, Olfa ^a   Penet, Anne Sophie ^a   Stella, Mattia ^a   Méeus, Pierre ^a   Orlandini, Florence ^a   Pérol, Maurice ^a   Fouchardière, Christelle De La ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IRINOTECAN; OXALIPLATIN; SULFAMETHOXAZOLE; TRIMETHOPRIM; VORICONAZOLE;

ADULT; ASPERGILLUS FUMIGATUS; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEBRILE NEUTROPENIA; HUMAN; LETTER; LUNG ASPERGILLOSIS; LUNG LAVAGE; MALE; MULTIPLE CYCLE TREATMENT; PANCREAS ADENOCARCINOMA; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPERGILLUS FUMIGATUS; CAMPTOTHECIN; FLUOROURACIL; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; MALE; MIDDLE AGED; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84872093877     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31825486f8     Document Type: Letter

References (10)

1. Roblot F, Godet C, Le Moal G, et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis. 2002;21:523-531.
2. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358-366.
3. Nicolle MC, Benet T, Thiebaut A, et al. Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. Haematologica. 2011;96:1685-1691.
4. Yan X, Li M, Jiang M, et al. Clinical characteristics of 45 patients with invasive pulmonary aspergillosis: retrospective analysis of 1711 lung cancer cases. Cancer. 2009;115:5018-5025.
5. Nivoix Y, Velten M, Letscher-Bru V, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis. 2008;47:1176-1184.
6. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825.
7. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46: 1813-1821.
8. Hughes WT, Feldman S, Aur RJ, et al. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer. 1975;36: 2004-2009.
9. Matsumura Y, Shindo Y, Iinuma Y, et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis. 1975;11:76.
10. Worth LJ, Dooley MJ, Seymour JF, et al. An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. Br J Cancer. 2005;92:867-872.